ABSTRACT
Felbamate is excreted into breast milk. Felbamate pharmacotherapy is recommended only for the symptomatic management of partial and generalized seizures associated with Lennox–Gastaut syndrome among children 2 years of age and older. For these children, initially prescribe 15 mg/kg daily orally in three or four divided doses. Increase the daily dosage at weekly intervals by increments of 15 mg/kg, as indicated by individual patient response. However, felbamate appears to increase the seizure threshold and reduce seizure spread primarily by means of the inhibition of voltage-dependent sodium ion channels. Concurrent felbamate and carbamazepine pharmacotherapy may result in an increased total body clearance of felbamate and a decreased carbamazepine blood concentration. Reportedly, the signs and symptoms of felbamate overdosage are mild and include gastric distress (mild), sleepiness (somnolence), and tachycardia.
